IGM BIOSCIENCES, INC. (IGMS): Price and Financial Metrics
GET POWR RATINGS... FREE!
IGMS POWR Grades
- IGMS scores best on the Value dimension, with a Value rank ahead of 45.33% of US stocks.
- The strongest trend for IGMS is in Quality, which has been heading up over the past 177 days.
- IGMS's current lowest rank is in the Momentum metric (where it is better than 5.13% of US stocks).
IGMS Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for IGMS is 0 -- better than merely 7.55% of US stocks.
- With a price/sales ratio of 1,351.15, IGM BIOSCIENCES INC has a higher such ratio than 99.62% of stocks in our set.
- Revenue growth over the past 12 months for IGM BIOSCIENCES INC comes in at 90.44%, a number that bests 90.74% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to IGM BIOSCIENCES INC are FATE, RLAY, ARVN, CCCC, and MORF.
- Visit IGMS's SEC page to see the company's official filings. To visit the company's web site, go to igmbio.com.
IGMS Valuation Summary
- In comparison to the median Healthcare stock, IGMS's EV/EBIT ratio is 138.38% lower, now standing at -3.8.
- IGMS's EV/EBIT ratio has moved up 27.2 over the prior 41 months.
Below are key valuation metrics over time for IGMS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| IGMS | 2023-01-20 | 1423.7 | 3.0 | -4.5 | -3.8 |
| IGMS | 2023-01-19 | 1445.2 | 3.1 | -4.6 | -3.9 |
| IGMS | 2023-01-18 | 1582.8 | 3.4 | -5.0 | -4.3 |
| IGMS | 2023-01-17 | 1577.9 | 3.4 | -5.0 | -4.3 |
| IGMS | 2023-01-13 | 1556.4 | 3.3 | -4.9 | -4.3 |
| IGMS | 2023-01-12 | 1510.9 | 3.2 | -4.8 | -4.1 |
IGMS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- IGMS has a Quality Grade of D, ranking ahead of 7.29% of graded US stocks.
- IGMS's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows IGMS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0 | NA | -0.989 |
| 2021-06-30 | 0 | NA | -0.807 |
| 2021-03-31 | 0 | NA | -0.567 |
| 2020-12-31 | 0 | NA | -0.435 |
| 2020-09-30 | 0 | NA | -0.350 |
| 2020-06-30 | 0 | NA | -0.345 |
IGMS Price Target
For more insight on analysts targets of IGMS, see our IGMS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $103.00 | Average Broker Recommendation | 1.33 (Strong Buy) |
IGMS Stock Price Chart Interactive Chart >
IGMS Price/Volume Stats
| Current price | $21.83 | 52-week high | $35.98 |
| Prev. close | $22.48 | 52-week low | $12.67 |
| Day low | $21.50 | Volume | 112,800 |
| Day high | $22.67 | Avg. volume | 210,574 |
| 50-day MA | $20.42 | Dividend yield | N/A |
| 200-day MA | $19.44 | Market Cap | 934.91M |
IGM BIOSCIENCES, INC. (IGMS) Company Bio
IGM Biosciences, Inc. operates as a biotechnology company which develops antibodies for the treatment of cancer. It offers IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The company was founded in 2010 and is headquartered in Mountain View, CA.
Latest IGMS News From Around the Web
Below are the latest news stories about IGM BIOSCIENCES INC that investors may wish to consider to help them evaluate IGMS as an investment opportunity.
IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid Tumors– Targeted IL-15/IL-15R IgM antibody to be evaluated for safety and pharmacodynamic effects – – Targeted IL-15/IL-15R IgM antibody to be evaluated for safety and pharmacodynamic effects – |
IGM Biosciences starts phase 1 trial of antibody therapy for solid tumorsIGM Biosciences (IGMS) said the first patient was dosed in a phase 1 trial of IGM-7354 for solid tumors.IGM-7354 is a targeted IL-15/IL-15R IgM antibody which could potentially be used… |
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development– Initial Data from Phase 1 combination with FOLFIRI shows promising activity in heavily pretreated metastatic colorectal cancer patients – – Encouraging safety profile in combination with FOLFIRI chemotherapy – – Randomized combination trial in second-line colorectal cancer patients to initiate in Q1 2023 – MOUNTAIN VIEW, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today |
IGM Biosciences to Present at the 41st Annual J.P. Morgan Healthcare ConferenceMOUNTAIN VIEW, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 5:15 p.m. PST in San Francisco. |
IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies at 2022 American Society of Hematology Annual MeetingFirst Preclinical Data for IGM-2644 and IGM-2537 Featured in Poster PresentationsMOUNTAIN VIEW, Calif., Dec. 11, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced the presentation of data from IGM’s expanding portfolio of T cell engagers for hematologic malignancies, including IGM-2644, IGM-2537 and imvotamab, at the 2022 American Society of Hematology (ASH) Annual Meeting and E |
IGMS Price Returns
| 1-mo | 28.34% |
| 3-mo | 19.16% |
| 6-mo | 18.38% |
| 1-year | 23.33% |
| 3-year | -35.78% |
| 5-year | N/A |
| YTD | 28.34% |
| 2022 | -42.00% |
| 2021 | -66.78% |
| 2020 | 131.37% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...